There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > NKG2D


Brief Information

Name:NKG2-D type II integral membrane protein
Target Synonym:KLRK1,CD314 Antigen,NKG2-D,Killer Cell Lectin Like Receptor K1,D12S2489E,KLR,DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence,Killer Cell Lectin-Like Receptor Subfamily K, Member 1,Killer cell lectin-like receptor subfamily K member 1,NK cell
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

FITC-Labeled Human NKG2D, Fc TagFITC-Labeled Human NKG2D, Fc Tag (Cat. No. NKD-HF224) ELISA bioactivity

Immobilized Human MICA, Fc Tag (MALS verified) (Cat. No. MIA-H5253) at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human NKG2D, Fc Tag (Cat. No. NKD-HF224) with a linear range of 0.156-10 μg/mL (QC tested).

Human NKG2D, Fc Tag (HPLC-verified) (Cat. No. ) HPLC images

The purity of Human NKG2D, Fc Tag (HPLC-verified) (Cat. No. NKD-H5265) was greater than 90% as determined by SEC-HPLC.

Synonym Name

NKG2D,CD314,KLRK1,NK cell receptor D


NKG2D is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors, also known as KLRK1, CD314, D12S2489E, KLR and killer cell lectin like receptor K1. NKG2D itself forms a homodimer whose ectodomains serve for ligand binding. NKG2D is a major recognition receptor for the detection and elimination of transformed and infected cells as its ligands are induced during cellular stress, either as a result of infection or genomic stress such as in cancer. In NK cells, NKG2D serves as an activating receptor, which itself is able to trigger cytotoxicity. The function of NKG2D on CD8+ T cells is to send co-stimulatory signals to activate them.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NKG2D CAR-T Cell therapy (Yake Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Leukemia, Myeloid, Acute Details
NKG2D CAR-T cell therapy (Uwell Biopharma) UWN2D Clinical Uwell Biopharma Neoplasms Details
Tesnatilimab IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 Phase 2 Clinical Innate Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Inflammation; Crohn Disease Details

This web search service is supported by Google Inc.